Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) infusion is associated with early toxicity. Yet, whether early toxicity development holds ramifications for long-term outcomes is unknown. METHODS: From a large cohort of consecutive adult patients treated with CAR-T therapies for relapsed or refr...

Descripción completa

Detalles Bibliográficos
Autores principales: Brammer, Jonathan E, Braunstein, Zachary, Katapadi, Aashish, Porter, Kyle, Biersmith, Michael, Guha, Avirup, Vasu, Sumithira, Yildiz, Vedat O, Smith, Sakima A, Buck, Benjamin, Haddad, Devin, Gumina, Richard, William, Basem M, Penza, Sam, Saad, Ayman, Denlinger, Nathan, Vallakati, Ajay, Baliga, Ragavendra, Benza, Raymond, Binkley, Philip, Wei, Lai, Mocarski, Mason, Devine, Steven M, Jaglowski, Samantha, Addison, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386216/
https://www.ncbi.nlm.nih.gov/pubmed/34429331
http://dx.doi.org/10.1136/jitc-2020-002303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386216/
https://www.ncbi.nlm.nih.gov/pubmed/34429331
http://dx.doi.org/10.1136/jitc-2020-002303

Ejemplares similares